<； p >； The present Invention relates to a Therapeutic Agent of Hunter Syndrome and, More specifically, a Therapeutic Agent of Hunter Syndrome.It can reduce the number of Hospital visits for Patients with Syndrome of Hunter Two Times a month or less containing a First composition to be injected intravenously andSecond composition via injected subcutaneously, which presents a medicinal effect equivalent to or greater than that of a conventional intravenous injection once a week,Increases the performance of the Taking of drugs by patients in comparison with the conventional therapeutic agents and Methods of TreatmentAnd allows Greater comfort and convenience for the patient.The Method of co injection (IV / SC according to the present Invention exhibits an equivalent or superior therapeutic effect compared with a conventional IV infusion once a week,While allowing a patient to visit the hospital with a Lower Frequency to once a week, as in conventional visits,Replacing the conventional method of intravenous injection once a week, which requires the patient to visit the hospital once a week,With SC injections through which a Predetermined number of times between IV injections can be performed directly by the custodian of the patient at home.This goes against the conventional concept that the effect achieved by SC injection therapy is not superior to therapeutic effect achieved by IV injection.Therefore,The present Invention relates to a Therapeutic Agent and a method of treatment, the effect of the treatment of Hunter Syndrome improves dramatically on a conventional Technology.<； / p >；<；p>；LA PRESENTE INVENCIÓ；N SE REFIERE A UN AGENTE TERAPÉ；UTICO DEL SÍ；NDROME DE HUNTER Y, MÁ；S ESPECÍ；FICAMENTE, A UN AGENTE TERAPÉ；UTICO DEL SÍ；NDROME DE HUNTER, QUE PUEDE REDUCIR EL NÚ；MERO DE VISITAS AL HOSPITAL POR PACIENTES CON EL SÍ；NDROME DE HUNTER A DOS VECES AL MES O MENOS AL CONTENER UNA PRIMERA COMPOSICI&Oacut
